Drugs / BOS-589
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03977155 | Jun 2019 → May 2020 | irritable bowel syndrome | Boston Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOS-589 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03977155 ↗ |
| Route | Oral | “Participants will receive a high dose of BOS-589 orally twice a day (BID).” NCT03977155 ↗ |